NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
- Conditions
- Cervical Squamous Cell CarcinomaRecurrent Cervical Cancer
- Interventions
- Biological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00025233
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Radiation: local irradiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00021229
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
- Conditions
- Malignant AscitesRecurrent Malignant MesotheliomaLocalized Malignant MesotheliomaAdvanced Malignant MesotheliomaPrimary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00028782
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00028561
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
- Conditions
- Adenocarcinoma of the RectumMucinous Adenocarcinoma of the RectumStage IIB Rectal CancerStage IIIC Rectal CancerSignet Ring Adenocarcinoma of the RectumStage IIA Rectal CancerStage IIC Rectal CancerStage IIIA Rectal CancerStage IIIB Rectal Cancer
- Interventions
- Radiation: radiation therapyProcedure: therapeutic conventional surgery
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00003799
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00017264
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission
- Interventions
- Procedure: peripheral blood stem cell transplantationProcedure: autologous hematopoietic stem cell transplantationProcedure: allogeneic hematopoietic stem cell transplantationRadiation: total-body irradiationBiological: filgrastimOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00039377
- Locations
- 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States
Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer
- Conditions
- Endometrial Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00030485
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019487
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019929
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States